David is an experienced life sciences executive with a passion for advancing innovations to the marketplace. As both an intra- and entrepreneur, he has led teams in a range of organizations, including multiple start-ups. David is currently leading the formation of the Indiana Biosciences Research Institute in Indianapolis, IN – a non-profit organization dedicated to discovery science and applied research in the areas of diabetes, cardio-metabolic disease, and poor nutrition, inspired by the state’s leading life sciences companies.

He is the former President and CEO of Alkermes helping to advance the commercialization of the company’s drug delivery technologies leading to the launch of numerous products including Risperdal Consta for psychosis, Bydureon for type 2 diabetes, and Vivitrol for dependence disorders.

David started his career at Eli Lilly and Company as an engineer and worked across the entire organization, including within the medical device and diagnostics division that was later spun-out as Guidant. While at Lilly, he supported development around blockbuster pharmaceutical brands including Ceclor, Prozac, and Zyprexa and led the launch of more than a dozen interventional vascular devices while leading new product development at Advanced Cardiovascular Systems.

David founded Zorion Medical in 2011 to develop fully absorbable, implantable devices for vascular disease and recently served as interim CEO for Apex Therapeutics, a cancer company focused on novel science discovered at Indiana University School of Medicine. He currently serves as an advisory to Embera, a company developing breakthrough products for the treatment of addictive disorders and is on the board of trustees at Wabash College.

David received his B.A. degree in chemistry, mathematics, and physics from Wabash College graduating summa cum laude and phi beta kappa. He went on to received his M.S. degree in chemical engineering from the Massachusetts Institute of Technology and his M.B.A. degree from the University of Chicago.